|Bid||5.55 x 1000|
|Ask||6.50 x 800|
|Day's Range||5.79 - 6.01|
|52 Week Range||5.79 - 11.68|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.67|
Subscribe to Yahoo Finance Plus to view Fair Value for CTSOLearn more
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb®1 blood purification, makes additional comments on the investigator-initiated REMOVE study following the formal presentation of trial results on Saturday, October 16th at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting in Barcelona, Spain.
For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative